Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 7, 2024
Daily News
October 7, 2024
- MHLW Issues Notification to Spur Use of RWD in Place of Clinical Trial Data
October 7, 2024
- Japan's 1st Nasal Flu Vaccine Now Available: Daiichi Sankyo
October 7, 2024
- MSD Curbs Supply of HPV Vaccines in Japan amid Catch-Up Demand
October 7, 2024
- New Health Minister to Stick to Honebuto Text on Off-Year Plan
October 7, 2024
- Enhertu Filed for HER2 Low or Ultralow Breast Cancer in Japan
October 7, 2024
- Ishiba Makes No Mention on Pharma in First Policy Speech
October 7, 2024
- J&J Eyes Double-Digit Growth in Japan Pharma Biz from 2027, 50 Approvals by 2029
October 7, 2024
- Non-HCPs Have Higher Expectations of Alzheimer’s Drugs than Specialists: Poll
October 7, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…